RxDoctor Payments Data

Jennifer Spors, NP

Gerontology · Indianapolis, INNPI 1003487604

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.1% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Abbott at 31.9% of the total.

$2,058in general payments, 2019–2025

Across 48 payments — averaging $42.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$657
  • AstraZeneca$292
  • Boehringer Ingelheim$241
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$136
  • Johnson & Johnson$119
  • Merck$112
  • plus $502 from 13 others

What the payments were for

  • Food & beverage$1,95895%
  • Education$1005%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,058 in reported general payments places this provider in the 80th percentile of 230 gerontology providers in Indiana.

See all gerontology providers in Indiana

Medicare billing

Part B allowed, 2024
$24,117
Medicare patients
159
Services billed
278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban87$89,549
EntrestoSacubitril/Valsartan37$44,421
XareltoRivaroxaban17$18,993
Diltiazem 24hr Er (Cd)Diltiazem Hcl41$1,068
Midodrine Hcl15$911
Amiodarone Hcl17$519
Atorvastatin Calcium31$442
Metoprolol Succinate84$434
Metoprolol Tartrate51$387
Furosemide82$344
Amlodipine Besylate35$330
Potassium Chloride29$296
Torsemide22$218
Carvedilol20$186
Losartan Potassium14$161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$58$89,54987 claims
NovartisEntresto$28$44,42137 claims
Johnson & JohnsonXarelto$119$18,99317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 230 gerontology providers in Indiana.

Other gerontology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →